Advertisement

EDITORIAL COMMENT

      This study provides additional evidence of the durability of the Rezūm procedure. The fact that this can be performed on an outpatient basis, in an ambulatory surgery center or office surgery setting, comports with other procedures that have evolved over the past decade (laser, transurethral microwave thermotherapy, transurethral needle ablation, etc.).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Pathak P.
        • Helo S.
        • McVary K.T.
        What's new in Rezūm?.
        Eur Urol Focus. 2018; 4: 32-35
        • Ahn H.S.
        • Kim S.J.
        • Choi J.B.
        • Choo S.H.
        • Shim K.H.
        • Kim S.I.
        Long-term cost comparison between surgical and medical therapy for benign prostatic hyperplasia: a study using hospital billing data.
        BJU Int. 2018; https://doi.org/10.1111/bju.14584
        • Gill B.C.
        • Ulchaker J.C.
        Costs of managing benign prostatic hyperplasia in the office and operating room.
        Curr Urol Rep. 2018; 19: 72
        • Westwood J.
        • Geraghty R.
        • Jones P.
        • Rai B.P.
        • Somani B.K.
        Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia.
        Ther Adv Urol. 2018; 10 (published online: August 12, 2018): 327-333
        • Martinelli E.
        • Herrmann T.
        Das Rezūm-System in der Behandlung der Blasenentleerungsstörung auf dem Boden einer gutartigen Prostatavergrößerung (BPO). The Rezūm system in the treatment of male lower urinary tract symptoms (LUTSs) due to benign prostatic obstruction (BPO).
        Aktuelle Urologie. 2018; 49: 519-524
        • Gandhi J.
        • Weissbart S.J.
        • Smith N.
        • et al.
        The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia.
        Translational Androl Urol. 2017; Vol 6